18923523 |
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma
Schleiermacher, G,
Lequin, D,
Pierron, G,
de Pontual, L,
Michon, J,
Valteau-Couanet, D,
Amiel, J,
Raynal, V,
Delattre, O,
Puisieux, A,
Lyonnet, S,
Ribeiro, A,
Frebourg, T,
Combaret, V,
Janoueix-Lerosey, I,
Brugières, L
|
Nature |
2008 |
21596819 |
Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene
Xing, M,
Murugan, AK
|
Cancer Res. |
2011 |
21838707 |
Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684
Schönherr, C,
Eriksson, T,
Christensen, J,
Palmer, RH,
Hallberg, B,
Ruuth, K,
Yamazaki, Y
|
Biochem J |
2011 |
27573755 |
The role of the ALK receptor in cancer biology
Hallberg, B,
Palmer, RH
|
Ann Oncol |
2016 |
24060861 |
Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology
Palmer, RH,
Hallberg, B
|
Nat. Rev. Cancer |
2013 |
25421750 |
Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma
Piazza, R,
Ceccon, M,
Giudici, G,
Mologni, L,
Fontana, D,
Gambacorti-Passerini, C,
Pirola, A
|
Mol. Cancer Res. |
2015 |
18724359 |
Identification of ALK as a major familial neuroblastoma predisposition gene
Hakonarson, H,
Kim, C,
Speleman, F,
Laureys, G,
Mossé, YP,
Hou, C,
Schork, NJ,
Maris, JM,
Tonini, GP,
Devoto, M,
Attiyeh, EF,
Rappaport, E,
Laudenslager, M,
Cole, KA,
Wood, A,
Lynch, JE,
Sennett, R,
Laquaglia, MJ,
Longo, L,
Torkamani, A,
Perri, P,
Brodeur, GM
|
Nature |
2008 |
23104988 |
Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma
Ohira, M,
Marra, MA,
Palmer, RH,
Nakagawara, A,
Attiyeh, EF,
Schönherr, C,
Kogner, P,
Sandström, PE,
Morozova, O,
Martinsson, T,
Maris, J,
Hallberg, B,
Ruuth, K,
Yamazaki, Y,
Chand, D
|
Dis Model Mech |
2013 |
29455642 |
Role and targeting of anaplastic lymphoma kinase in cancer
Troiani, T,
Viscardi, G,
Morgillo, F,
Fasano, M,
Martinelli, E,
Ciardiello, F,
Della Corte, CM,
Di Liello, R
|
Mol. Cancer |
2018 |
18923525 |
Activating mutations in ALK provide a therapeutic target in neuroblastoma
Zozulya, S,
George, RE,
Gilliland, DG,
Morris, SW,
Luther, W,
London, WB,
Hanna, M,
Meyerson, M,
McGrady, P,
Sanda, T,
Gregor, VE,
Look, AT,
Zhang, J,
Fröhling, S,
Ahn, Y,
Diller, L,
Webb, TR,
Zhou, W,
Greulich, H,
Gray, NS,
Xue, L
|
Nature |
2008 |
23239810 |
Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors
Ceccon, M,
Mologni, L,
Scapozza, L,
Bisson, W,
Gambacorti-Passerini, C
|
Mol. Cancer Res. |
2013 |
23201355 |
Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition
Roskoski, R
|
Pharmacol. Res. |
2013 |
21847362 |
Identification of oncogenic point mutations and hyperphosphorylation of anaplastic lymphoma kinase in lung cancer
Lin, SC,
Tu, PH,
Wang, YW,
Lin, KT,
Jou, YS,
Ko, JY
|
Neoplasia |
2011 |
18923524 |
Oncogenic mutations of ALK kinase in neuroblastoma
Ohira, M,
Kikuchi, A,
Soda, M,
Kato, M,
Choi, YL,
Nakagawara, A,
Hayashi, Y,
Wang, L,
Ogawa, S,
Chen, Y,
Sanada, M,
Takita, J,
Mano, H,
Igarashi, T
|
Nature |
2008 |